The present invention relates to modified antigen binding molecules (ABMs). Inparticular embodiments, the present invention relates to recombinant monoclonal antibodiesor fragments, including chimeric, primatized or humanized antibodies or fragments,having altered ability to mediate cell signaling activity by a target antigen,and/or altered ability to mediate cross-linking of one or more target antigens.In addition, the present invention relates to nucleic acid molecules encodingsuch modfied ABMs, and vectors and host cells comprising such nucleic acid molecules.The invention further relates to methods for producing the modified ABMs of theinvention, and to methods of using these modified ABMs in treatment of disease.In addition, the present invention relates to modified ABMs with modified glycosylationhaving improved therapeutic properties, including antibodies with increasedFc receptor binding and increased effector function.
